Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $75.6M | $124M |
| Revenue growth | — | — | — | — | — | 63.5% |
| Operating income | -$28.0M | -$72.9M | -$112M | -$143M | -$81.1M | -$54.2M |
| Operating margin | — | — | — | — | -107.3% | -43.8% |
| Net income | -$35.9M | -$74.0M | -$109M | -$135M | -$72.7M | -$38.6M |
| Net margin | — | — | — | — | -96.1% | -31.2% |
| EPS (diluted) | -$23.65 | -$2.96 | — | — | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$23.1M | -$59.4M | -$92.5M | -$43.8M | $42.0M | -$22.8M |
| Capital expenditures | $3.39M | $9.73M | $12.9M | $19.0M | $3.99M | $4.70M |
| Free cash flow | -$26.4M | -$69.1M | -$105M | -$62.8M | $38.0M | -$27.5M |
| Dividends paid | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.7M | $346M | $54.9M | $128M | $224M | $130M |
| Total assets | $49.4M | $366M | $342M | $304M | $439M | $449M |
| Total liabilities | $30.3M | $18.8M | $71.0M | $125M | $216M | $216M |
| Shareholders' equity | -$48.7M | $348M | $271M | $179M | $223M | $233M |
| Retained earnings | -$48.1M | -$122M | -$231M | -$366M | -$439M | -$477M |
| Shares (wtd avg diluted) | 1.69M | 25.0M | 47.2M | 51.4M | 73.9M | 83.1M |
Every figure is extracted from Monte Rosa Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.